AR025455A1 - Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos - Google Patents

Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos

Info

Publication number
AR025455A1
AR025455A1 ARP000104536A ARP000104536A AR025455A1 AR 025455 A1 AR025455 A1 AR 025455A1 AR P000104536 A ARP000104536 A AR P000104536A AR P000104536 A ARP000104536 A AR P000104536A AR 025455 A1 AR025455 A1 AR 025455A1
Authority
AR
Argentina
Prior art keywords
contraception
mesoprogestines
conceptives
components
female
Prior art date
Application number
ARP000104536A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR025455A1 publication Critical patent/AR025455A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP000104536A 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos AR025455A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
AR025455A1 true AR025455A1 (es) 2002-11-27

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104536A AR025455A1 (es) 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos

Country Status (28)

Country Link
EP (1) EP1605949A2 (bg)
JP (1) JP2003511399A (bg)
KR (1) KR20020038745A (bg)
CN (1) CN1384748A (bg)
AR (1) AR025455A1 (bg)
AU (1) AU781835B2 (bg)
BG (1) BG106441A (bg)
BR (1) BR0013711A (bg)
CA (1) CA2383650A1 (bg)
CO (1) CO5190694A1 (bg)
CZ (1) CZ2002707A3 (bg)
EA (1) EA006805B1 (bg)
EE (1) EE200200103A (bg)
HR (1) HRP20020265A2 (bg)
HU (1) HUP0202515A3 (bg)
IL (1) IL148415A0 (bg)
LT (1) LT5001B (bg)
LV (1) LV12940B (bg)
MX (1) MXPA02002186A (bg)
NO (1) NO20020998L (bg)
NZ (1) NZ517470A (bg)
PE (1) PE20010579A1 (bg)
PL (1) PL353994A1 (bg)
SI (1) SI20853A (bg)
SK (1) SK2982002A3 (bg)
UA (1) UA77150C2 (bg)
WO (1) WO2001026603A2 (bg)
YU (1) YU13902A (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
AU2003255355A1 (en) * 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
EP1773344A1 (en) * 2004-07-07 2007-04-18 Wyeth a Corporation of the State of Delaware Cyclic progestin regimens and kits
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
ES2602134T3 (es) 2009-04-14 2017-02-17 Laboratoire Hra Pharma Procedimiento para anticoncepción bajo demanda
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
DK174071B1 (da) * 1987-09-24 2002-05-21 Jencap Res Ltd Kontraceptivt præparat i form af en pakning omfattende enhedsdoser
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429398C2 (de) 1994-08-09 1997-09-11 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
NZ295365A (en) * 1994-10-24 1999-07-29 Schering Ag Competitive progesterone antagonists for regulating female fertility as required
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
CA2255863A1 (en) * 1996-06-25 1997-12-31 Akzo Nobel Nv Progestogen-anti-progestogen regimens
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
CA2371273A1 (en) * 1999-05-04 2000-11-09 Andrew Fensome Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
PE20010579A1 (es) 2001-06-04
BR0013711A (pt) 2002-05-07
BG106441A (bg) 2002-09-30
CN1384748A (zh) 2002-12-11
YU13902A (sh) 2006-01-16
NZ517470A (en) 2004-03-26
HUP0202515A3 (en) 2004-06-28
WO2001026603A2 (en) 2001-04-19
AU781835B2 (en) 2005-06-16
CZ2002707A3 (cs) 2002-11-13
HRP20020265A2 (en) 2004-02-29
HUP0202515A2 (hu) 2002-12-28
NO20020998D0 (no) 2002-02-28
UA77150C2 (en) 2006-11-15
KR20020038745A (ko) 2002-05-23
NO20020998L (no) 2002-03-14
CA2383650A1 (en) 2001-04-19
EP1605949A2 (en) 2005-12-21
JP2003511399A (ja) 2003-03-25
LT2002035A (lt) 2002-10-25
MXPA02002186A (es) 2002-09-02
EA006805B1 (ru) 2006-04-28
SK2982002A3 (en) 2002-07-02
EA200200284A1 (ru) 2002-10-31
PL353994A1 (en) 2003-12-15
SI20853A (sl) 2002-10-31
LT5001B (lt) 2003-03-25
AU3215001A (en) 2001-04-23
EE200200103A (et) 2003-04-15
LV12940B (en) 2003-06-20
CO5190694A1 (es) 2002-08-29
WO2001026603A3 (en) 2002-01-17
IL148415A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
CA2256365A1 (en) Compositions, methods and devices for the transdermal delivery of drugs
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
PT87053A (pt) Processo para a preparacao de composicoes contraceptivas contendo meletonina e metodo para efectuar a contracepcao
PE20051038A1 (es) Uso extendido de combinacion que comprende estrogenos y progestinas
EP1260206A3 (en) Pants-type disposable wearing article
DK0836506T3 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
NO20024908D0 (no) 8<beta>-hydrokarbyl-substituerte östratriener for anvendelse som selektive östrogener
ATE288744T1 (de) Arzneiformulierungen zur hormonersatztherapie zur topischen anwendung auf der haut
AR035904A1 (es) 5-[2-hidroxi-3-1-(3-trifluorometilfenil)-ciclopropil-propionilamino]-ftalida y compuestos relacionados con actividad moduladora del receptor de progesterona
AR025455A1 (es) Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos
EA200900451A1 (ru) Способ получения композиции эстрадиола с медленным высвобождением ( варианты ), микросферы эстрадиола и холестерина и способ для одновременной контрацепции и гормонозамещения
ES2162900T3 (es) Composicion liquida de l-n-mentol y procedimiento para su preparacion.
AR016502A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas.
BR0214634A (pt) Sistemas terapêuticos transdérmicos contendo hormÈnio esteróide e contendo monocaprilato de propilenoglicol
PE20060318A1 (es) Forma de administracion para la contracepcion hormonal
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
BR0210272A (pt) Absorvente labial com dispositivo auxiliar para posicionamento e recepção de dedo
AR025457A1 (es) Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes
AR025456A1 (es) Mesoprogestinas (moduladores de receptor de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (trh)
BR0214334A (pt) Método para prover uma composição de base tópica para uso na preparação de uma composição cosmética, recipiente cosmético re-selável, e, composição anidra
DE10250470A1 (de) Körperhygieneartikel aus saugfähigem Material - Urin-Rest-Absorber (URA) für Männer
CN2452478Y (zh) 髋部包扎带
KR970005295A (ko) 죽염과 운모를 유효성분으로 함유하는 질정제
ATE546144T1 (de) Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysf unktionellen uterinen blutung in einheit mit einer oralen kontrazeption
Khomasuridze et al. Characteristics of progestin use in pre-menopausal women

Legal Events

Date Code Title Description
FB Suspension of granting procedure